Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM-303/InterAACT2 trial of retifanlimab plus chemotherapy for squamous cell ...
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously ...
Up to now, patients with inoperable anal cancer, a rare disease, have not had a standard-of-care treatment; palliative care has been the routine for them. Now, results from InterAAct, the first ...
Hosted on MSN
New Phase 3 Trial Data Positions Retifanlimab as Breakthrough in Advanced SCAC Treatment
WILMINGTON, DE — Groundbreaking results from the Phase 3 POD1UM-303/InterAACT 2 trial have been published in The Lancet, showcasing the efficacy of retifanlimab (Zynyz®) in combination with ...
Combining retifanlimab (Zynyz) with standard-of-care chemotherapy significantly improved progression-free survival (PFS) in treatment-naïve patients with locally advanced or metastatic squamous cell ...
Up to now, patients with inoperable anal cancer, a rare disease, have not had a standard-of-care treatment; palliative care has been the routine for them. Now, results from InterAAct, the first ...
Carboplatin plus paclitaxel should now be considered the standard of care for patients with advanced anal cancer, in place of the standard combination of 5-fluorouracil (5-FU) and cisplatin, say ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results